Gene Therapy for Neuropsychiatric Disorders: Potential Targets and Tools.

Shahcheraghi, SH; Ayatollahi, J; Lotfi, M; Aljabali, AAA; Al-Zoubi, MS; Panda, PK; Mishra, V; Satija, S; Charbe, NB; Serrano-Aroca, Á; Bahar, B; Takayama, K; Goyal, R; Bhatia, A; Almutary, AG; Alnuqaydan, AM; Mishra, Y; Negi, P; Courtney, A; McCarron, PA; Bakshi, HA; Tambuwala, MM

Gene Therapy for Neuropsychiatric Disorders: Potential Targets and Tools.

Shahcheraghi, SH Ayatollahi, J Lotfi, M Aljabali, AAA Al-Zoubi, MS Panda, PK Mishra, V Satija, S

Charbe, NB Serrano-Aroca, Á Bahar, B Takayama, K Goyal, R Bhatia, A Almutary, AG Alnuqaydan, AM Mishra, Y Negi, P Courtney, A McCarron, PA Bakshi, HA Tambuwala, MM

Permalink

Publisher:: BENTHAM SCIENCE PUBL
Publication Type:: Journal Article
Citation:: CNS Neurol Disord Drug Targets, 2023, 22, (1), pp. 51-65
Issue Date:: 2023

Closed Access

	Filename	Description	Size
	22305002_13393116900005671.pdf	Published version	4.47 MB	Adobe PDF	View/Open

Copyright Clearance Process

Recently Added
In Progress
Closed Access

This item is closed access and not available.

Full metadata record

Field	Value	Language
dc.contributor.author	Shahcheraghi, SH
dc.contributor.author	Ayatollahi, J
dc.contributor.author	Lotfi, M
dc.contributor.author	Aljabali, AAA
dc.contributor.author	Al-Zoubi, MS
dc.contributor.author	Panda, PK
dc.contributor.author	Mishra, V
dc.contributor.author	Satija, S https://orcid.org/0000-0003-4702-6534
dc.contributor.author	Charbe, NB
dc.contributor.author	Serrano-Aroca, Á
dc.contributor.author	Bahar, B
dc.contributor.author	Takayama, K
dc.contributor.author	Goyal, R
dc.contributor.author	Bhatia, A
dc.contributor.author	Almutary, AG
dc.contributor.author	Alnuqaydan, AM
dc.contributor.author	Mishra, Y
dc.contributor.author	Negi, P
dc.contributor.author	Courtney, A
dc.contributor.author	McCarron, PA
dc.contributor.author	Bakshi, HA
dc.contributor.author	Tambuwala, MM
dc.date.accessioned	2024-03-26T22:49:31Z
dc.date.available	2022-01-16
dc.date.available	2024-03-26T22:49:31Z
dc.date.issued	2023
dc.identifier.citation	CNS Neurol Disord Drug Targets, 2023, 22, (1), pp. 51-65
dc.identifier.issn	1871-5273
dc.identifier.issn	1996-3181
dc.identifier.uri	http://hdl.handle.net/10453/177201
dc.description.abstract	Neuropsychiatric disorders that affect the central nervous system cause considerable pressures on the health care system and have a substantial economic burden on modern societies. The present treatments based on available drugs are mostly ineffective and often costly. The molecular process of neuropsychiatric disorders is closely connected to modifying the genetic structures inherited or caused by damage, toxic chemicals, and some current diseases. Gene therapy is presently an experimental concept for neurological disorders. Clinical applications endeavor to alleviate the symptoms, reduce disease progression, and repair defective genes. Implementing gene therapy in inherited and acquired neurological illnesses entails the integration of several scientific disciplines, including virology, neurology, neurosurgery, molecular genetics, and immunology. Genetic manipulation has the power to minimize or cure illness by inducing genetic alterations at endogenous loci. Gene therapy that involves treating the disease by deleting, silencing, or editing defective genes and delivering genetic material to produce therapeutic molecules has excellent potential as a novel approach for treating neuropsychiatric disorders. With the recent advances in gene selection and vector design quality in targeted treatments, gene therapy could be an effective approach. This review article will investigate and report the newest and the most critical molecules and factors in neuropsychiatric disorder gene therapy. Different genome editing techniques available will be evaluated, and the review will highlight preclinical research of genome editing for neuropsychiatric disorders while also evaluating current limitations and potential strategies to overcome genome editing advancements.
dc.format	Print
dc.language	eng
dc.publisher	BENTHAM SCIENCE PUBL
dc.relation.ispartof	CNS Neurol Disord Drug Targets
dc.relation.isbasedon	10.2174/1871527321666220304153719
dc.rights	info:eu-repo/semantics/closedAccess
dc.subject	1109 Neurosciences, 1115 Pharmacology and Pharmaceutical Sciences
dc.subject.classification	Neurology & Neurosurgery
dc.subject.classification	3209 Neurosciences
dc.subject.classification	3214 Pharmacology and pharmaceutical sciences
dc.subject.mesh	Humans
dc.subject.mesh	Genetic Therapy
dc.subject.mesh	Mental Disorders
dc.subject.mesh	Humans
dc.subject.mesh	Mental Disorders
dc.subject.mesh	Genetic Therapy
dc.subject.mesh	Humans
dc.subject.mesh	Genetic Therapy
dc.subject.mesh	Mental Disorders
dc.title	Gene Therapy for Neuropsychiatric Disorders: Potential Targets and Tools.
dc.type	Journal Article
utslib.citation.volume	22
utslib.location.activity	United Arab Emirates
utslib.for	1109 Neurosciences
utslib.for	1115 Pharmacology and Pharmaceutical Sciences
pubs.organisational-group	University of Technology Sydney
pubs.organisational-group	University of Technology Sydney/Faculty of Science
utslib.copyright.status	closed_access	*
dc.date.updated	2024-03-26T22:49:29Z
pubs.issue	1
pubs.publication-status	Published
pubs.volume	22
utslib.citation.issue	1

Abstract:

Neuropsychiatric disorders that affect the central nervous system cause considerable pressures on the health care system and have a substantial economic burden on modern societies. The present treatments based on available drugs are mostly ineffective and often costly. The molecular process of neuropsychiatric disorders is closely connected to modifying the genetic structures inherited or caused by damage, toxic chemicals, and some current diseases. Gene therapy is presently an experimental concept for neurological disorders. Clinical applications endeavor to alleviate the symptoms, reduce disease progression, and repair defective genes. Implementing gene therapy in inherited and acquired neurological illnesses entails the integration of several scientific disciplines, including virology, neurology, neurosurgery, molecular genetics, and immunology. Genetic manipulation has the power to minimize or cure illness by inducing genetic alterations at endogenous loci. Gene therapy that involves treating the disease by deleting, silencing, or editing defective genes and delivering genetic material to produce therapeutic molecules has excellent potential as a novel approach for treating neuropsychiatric disorders. With the recent advances in gene selection and vector design quality in targeted treatments, gene therapy could be an effective approach. This review article will investigate and report the newest and the most critical molecules and factors in neuropsychiatric disorder gene therapy. Different genome editing techniques available will be evaluated, and the review will highlight preclinical research of genome editing for neuropsychiatric disorders while also evaluating current limitations and potential strategies to overcome genome editing advancements.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/177201